Elecoglipron, regardless of dose, placebo and semaglutide were administered once daily as oral tablets
Therefore, continuous assessment is also required to determine the cost-effectiveness of the combination therapy
Cheek measurements went up, not down
Tsukamoto S, Morita R, Yamada T, et al
GLP-1 Receptor agonists in diabetic kidney disease: from clinical outcomes to mechanisms
[10] [11] Based on data from retatrutide clinical trials (NEJM, 2023) and experience with similar approved agents, patients may experience: Redness, swelling, or itching at the injection site, which typically resolves within a few hours to days Bruising or mild pain immediately following injection Nodules or localised reactions beneath the skin, which may occur with repeated injections at the same site These reactions are generally mild and self-limiting